Atrial natriuretic peptide and dopamine in a rat model of ischemic acute renal failure

Abstract

Atrial natriuretic peptide (ANP) has been shown to reverse experimental models of ischemic acute renal failure (ARF). However, infusion of ANP has been associated with systemic hypotension making its use in clinical ARF impractical. Therefore, in this investigation, dopamine (D) was combined with intravenous (i.v.) atriopeptin III (AP III) to determine if this regimen was effective in reversing ARF while preventing systemic hypotension and maintaining renal blood flow (RBF). Four groups of Munich-Wistar rats were studied. Group 1, sham-ARF; Group 2, renal artery (RA) clamp (55 min) followed by i.v. saline; Group 3, RA clamp followed by i.v. AP III-D; and Group 4, RA clamp followed by i.v. D only. All infusions were begun after RA clamp release and continued for four hour. Mean arterial pressure in Group 3 rats given AP III-D were similar to that in Group 2, slightly less than that in Groups 1 and 4 (P less than 0.05), but consistently greater than 100 mm Hg during the four hour infusion. RBF in Group 3 was elevated above the level in Group 1 at P less than 0.05. Glomerular filtration rate (GFR), depressed by 52% in Group 2, was corrected to control (sham-ARF) levels in Group 3. In Group 4 there was a small but significant increase in GFR compared to Group 2 (P less than 0.05), but it remained less than that in sham-ARF or AP III-D treated ARF rats (P less than 0.01). Urine flow rate and urine sodium excretion rate were more than sixfold higher in Group 3 than any other group.(ABSTRACT TRUNCATED AT 250 WORDS)

Atrial Natriuretic Factor Infusion following Acute Renal Ischemia in Anesthetized Dogs

“…Since the renal response to ANF is dose dependent, a greater benefit has usually been found to be associated with infusion rates that cause hypotension. A combined ap plication of ANF and dopamine has been re ported to circumvent this problem [3]. A fall in BP was observed at doses of 200 ng/min x kgBW or more [2,18]; however, since plasma concentrations of ANF were not monitored in these studies, a correlation between ANF plasma level and a fall in BP has not been definitely established.…”

Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats

“…Importantly, the combination therapy of both enalapril and paricalcitol had a more marked effect and totally inhibited the rise in ANP. Several studies indicate that in addition to its effects on regulation of volume and BP, ANP can act to preserve renal function (7,34). Koga et al (25) showed in rats that ANP also has antioxidant effects as demonstrated by its ability to attenuate ROS levels in a renal ischemia-reperfusion (I/R) injury model.…”

Protection of Glucagon-Like Peptide-1 in Cisplatin-Induced Renal Injury Elucidates Gut-Kidney Connection

“…10 The renoprotective effect of GLP-1 in this study might have some relation to the previously reported renoprotection by ANP. 48,49 It remains uncertain whether DPP-4 inhibition and GLP-1 pathway mediation interfere with the antitumor effects of CP. Additional experiments must be conducted before our findings can be translated to clinical use.…”